AzTrials
AzTrials

Observational StudyNCT05135013

The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study

An observational study of Observational Study, run by NewGiza University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females. Read more about this study

Who is it for?
Ages 18 to 70 years, women onlyHealthy volunteers can take part
Conditions the study is for
Observational Study
What is being tested?
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
Type of treatment
Pill or oral medicine
How many people
200 participants
Where
No sites listed yet
Study dates
16 Nov 2021to 31 Mar 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Eligible candidates will be stratified as cases or matched controls as follows: 1. Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). 2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.

Who may be able to join

  • Age > 18 and < 70

Who cannot join

  • Diagnosed with other concurrent malignancies.
  • A prior history of another cancer.

Trial locations and contacts

No sites are listed yet.

Nermeen Ashoush, PhD contact

+201001809397

nermeen.ashoush@ngu.edu.eg

About this study

The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females.

Read the detailed description

Methodology Design. A case-controlled study.

Setting. Breast cancer clinic and breast cancer screening unit at clinical oncology department, Ain Shams University hospital

Participants.

All cases who will be screened from the BC clinic and the BC screening unit will be assessed for eligibility according to the following inclusion \& exclusion criteria:

Inclusion criteria

Age > 18 and < 70

Exclusion criteria

  • Diagnosed with other concurrent malignancies.
  • A prior history of another cancer.

Eligible candidates will be stratified as cases or matched controls as follows:

  1. Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
  2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.

Ethical consideration. The protocol will be approved by the ethical committee of NGU and the Clinical Oncology department ASU. The study will be registered at clinicaltrials.gov

Methods.

Data collection for both groups will be done through reviewing of the participants' medical records retrospectively Data collection will include the following data:

  • Demographic data: name, age, sex, residence
  • Anthropometric data: height, weight, waist \& hip circumference \& waist to hip ratio and BMI calculation
  • Female \& menopausal status, age at menarche
  • Medical history \& comorbidity (CVS, DM 1 or 2, HTN)
  • Family history of other cancers, diabetes
  • Occupational history
  • Social history: smoking, recreational drug use, marital status, nulliparity/multi-parity and lactation
  • Dietary habits and diet composition
  • Lifestyle habits and degree of regular activity (sedentary, active, etc.)
  • History of hormonal use as follows:
  1. Reason for hormonal use: contraception, fertility promotion, PCOS
  2. Duration of hormonal use
  3. Type of hormonal drug used: dose, hormone type, route of administration
  • Breast cancer classification:
  1. - Type of pathology - 2- Molecular classification (ER, PR, Her2 receptors status) 3- Staging of BC.

Statistical analysis The frequency distribution of the parameters will be assessed. Parametric data will be presented as mean \& standard deviation, while non parametric data will be presented as median \& IQR. All data will be analyzed using the appropriate statistical test. Proportions will be presented using number \& proportion and will be assessed by the Chi square.

Multiple logistic regression analysis will be used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for the various studied factors in relation to breast cancer occurrence \& subtypes.

Moreover, the effect of the combined significant factors to the risk of breast cancer development will be evaluated.

Being tested
Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
Keywords
Hormonal Intake, Breast Cancer Risk, Demographic Factors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiolDrug

    History of hormonal use as follows:

    1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)
    2. Duration of hormonal use
    3. Type of hormonal drug used: dose, hormone type, route of administration
Study groups in NCT05135013
Study groupRoleWhat they receive
Cases1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
Receives: Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
Matched Controls2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
Receives: Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Confirmed Breast Cancer Patients

    Patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).

    Measured: During the past 2 years to 2021 (2019-2020).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2021
  2. Study start16 Nov 2021 (estimated)
  3. Primary completion31 Jan 2022 (estimated)
  4. Study completion31 Mar 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05135013
Sponsor's protocol ID
NewGiza University Protocol 1
Status last verified
Nov 2021
First submitted
16 Nov 2021
Last updated
26 Nov 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Observational Study, run by NewGiza University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nermeen Ashoush, PhD (+201001809397, nermeen.ashoush@ngu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Confirmed Breast Cancer Patients (time frame: During the past 2 years to 2021 (2019-2020).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in